Myriad Genetics (MYGN) Misses Q4 EPS by 6c; Issues Weak Q1, FY17 Outlook

Jefferies Remains Sidelined on Myriad Genetics (MYGN) Following 4Q

Jefferies maintained a Hold rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $20.00 (from $34.00), following the company's 4Q earnings report. The company's weaker 4Q16 experience (-7%) and initial FY17 outlook for the HC segment (-7%) suggest pricing and... More

Barclays Downgrades Myriad Genetics (MYGN) to Equalweight

Barclays downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Equalweight with a price target of $24.00 (from $50.00).

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $29.46 yesterday.

Mizuho Securities Cuts Price Target on Myriad Genetics (MYGN) to $22 Following 4Q and Guidance

Mizuho Securities maintained a Neutral rating on Myriad Genetics (NASDAQ: MYGN), and cut the price target to $22.00 (from $34.00), following the company's 4Q results and guidance. MYGN guided to 2017 revenues of $740mm-$760mm, versus consensus of $790mm, and EPS of $1.00-$1.10, versus consensus of $1.77.... More

Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform

Wells Fargo downgraded Myriad Genetics (NASDAQ: MYGN) from Outperform to Market Perform.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $29.46 yesterday.

Piper Jaffray Downgrades Myriad Genetics (MYGN) to Neutral

Piper Jaffray downgraded Myriad Genetics (NASDAQ: MYGN) from Overweight to Neutral with a price target of $22.00 (from $47.00).

Analyst William Quirk commented, "Myriad's 4Q16 revenue declined 1.8% yoy to $186.5M, below our in line estimate of $187.7M. EPS of $0.36 was below our in line $0.37 estimate.... More

Myriad Genetics (MYGN) halted with news pending

Myriad Genetics (NASDAQ: MYGN) halted with news pending.